![]() |
|
|
Vol. 295, Issue 2, 627-633, November 2000
1A/
1L-Adrenoceptor Mediates
Contraction of Canine Subcutaneous Resistance Arteries1
Autonomic Physiology Unit, Division of Neuroscience and Biomedical
Systems, Institute of Biomedical & Life Sciences, University of
Glasgow, Glasgow, Scotland, United Kingdom
To determine the characteristics of the
1-adrenoceptor subtypes involved in adrenergic
regulation of peripheral vascular resistance, contraction of canine
subcutaneous resistance arteries was studied using wire myographs. The
potencies of agonists and antagonists, chosen for their ability to
discriminate between
1-adrenoceptor subtypes, were
assessed in the presence of cocaine (3 µM), corticosterone (30 µM),
and propranolol (1 µM). The rank order of agonist potency
(pEC50 ± S.E.) was (R)-A-61603
(7.88 ± 0.1) > norepinephrine (6.41 ± 0.1) > phenylephrine (5.83 ± 0.1). The high sensitivity to
(R)-A-61603 relative to phenylephrine is inconsistent
with the presence of the
1D-adrenoceptor and most
consistent with an
1A-adrenoceptor response. This is
supported by the low affinity for the
1D-selective
antagonist BMY 7378 (pKB 6.51 ± 0.47).
The low pA2 values for prazosin (8.36) and HV723
(8.81), by definition, indicate the involvement of the putative
1L-adrenoceptor, a hypothesis supported by the
pA2 values for WB4101 (8.42) and 5-methyl-urapidil (8.08).
Pre-exposure to 1 µM CEC had little effect, whereas 100 µM CEC
reduced the maximum contraction but not the sensitivity to
norepinephrine. This low sensitivity to CEC argues against the presence
of the
1B-adrenoceptor. We conclude that, by current
definitions, an
1A-/
1L-adrenoceptor causes contraction of these vessels. This does not support the concept
that selectivity for the
1A-adrenoceptor is the basis for the effectiveness of some
-blockers in some tissues, such as
prostate, but not in other tissues such as blood vessels. Rather, the
generally low potency of
-blockers in some tissues may be due to a
tissue-specific property of the receptors.
This article has been cited by other articles:
![]() |
D. Marti, R. Miquel, K. Ziani, R. Gisbert, M. D. Ivorra, E. Anselmi, L. Moreno, V. Villagrasa, D. Barettino, and P. D'Ocon Correlation between mRNA levels and functional role of {alpha}1-adrenoceptor subtypes in arteries: evidence of {alpha}1L as a functional isoform of the {alpha}1A-adrenoceptor Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1923 - H1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Daly, C. Deighan, A. McGee, D. Mennie, Z. Ali, M. McBride, and J. C. McGrath A knockout approach indicates a minor vasoconstrictor role for vascular {alpha}1B-adrenoceptors in mouse Physiol Genomics, May 10, 2002; 9(2): 85 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Guimaraes and D. Moura Vascular Adrenoceptors: An Update Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356. [Abstract] [Full Text] [PDF] |
||||